aspirin (ASA)

DRUG4 trials

Sponsors

Abbott, Maria Sklodowska-Curie National Research Institute of Oncology, Janssen Scientific Affairs, LLC

Conditions

Atrial FibrillationDyslipidemiaGastrointestinal HemorrhagePercutaneous Coronary Intervention

Phase 3

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

CompletedNCT00626392

AbbottDyslipidemia

Start: 2008-02-29End: 2008-04-30Updated: 2009-09-02

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

CompletedNCT00630877

AbbottDyslipidemia

Start: 2008-02-29End: 2008-06-30Updated: 2009-10-09

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

CompletedNCT01830543

Janssen Scientific Affairs, LLCAtrial Fibrillation, Percutaneous Coronary Intervention

Start: 2013-05-10End: 2016-07-28Updated: 2017-09-19

Phase 4

The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin

Maria Sklodowska-Curie National Research Institute of OncologyGastrointestinal Hemorrhage

Start: 2012-09-30End: 2015-09-30Target: 760Updated: 2012-03-09

Related Papers

Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis.

2020-01-0135 citations

Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation

Circulation Cardiovascular Interventions2019-11-013 citations

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2019-02-0111 citations

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

2018-10-0110 citations

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.

2018-03-1424 citations

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Circulation2016-11-1595 citations

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

New England Journal of Medicine2016-11-141525 citations

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).

2014-12-20102 citations

Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.

2009-01-0115 citations